ImmuCell Corp. (NASDAQ:ICCC) of Portland, Maine, hasappointed Thomas Hatch, formerly manager of commercialdevelopment, to president and chief executive officer. Hereplaces Thomas Adelman, who was appointed chairman.Michael F. Brigham, formerly director of finance andadministration, was named chief financial officer of the makerof human and bovine diagnostics.

George R. Evanega, Ph.D., was named president and chiefoperating officer of Oncor Inc. Evanega was corporate vicepresident, chief administrative officer and a director of MilesInc. Oncor (NASDAQ:ONCR) of Gaithersburg, Md., manufacturesand markets DNA probes.

David W. Ortlieb and Richard R. Pivirotto have been nominatedto the board of Immunomedics Inc. Ortlieb is president andchief executive officer of Texas Biotechnology Corp. Pivirottois president of Richard R. Pivirotto Co. Inc. Also, board memberWilliam H. Rorer III will consult to the company in the planningand selection of its future commercial-scale manufacturingfacility. The company also named Dr. Dennis Fowler assistantvice president of clinical affairs and Charles Katzer directorof operations/quality assurance. Immunomedics (NASDAQ:IMMU) of Warren, N.J., is developing products for the detectionand treatment of cancers and infectious diseases.

Glycomed Inc. said Mark Moran will be vice president ofmedical affairs. Moran was senior director of clinical researchat G.D. Searle & Co. Glycomed (NASDAQ:GLYC) of Alameda,Calif., is developing pharmaceuticals based on complexcarbohydrates.

ImmuLogic Pharmaceutical Corp. has appointed MalcolmMorville senior vice president of development and preclinicalresearch. Since 1988, Morville has been vice president ofresearch and development. ImmuLogic Pharmaceutical(NASDAQ:IMUL) of Cambridge, Mass., is developing products totreat allergies and autoimmune diseases.

Natural Product Sciences Inc. of Salt Lake City has namedJames U. Jensen vice president for corporate development andlegal affairs. Jensen was founding partner and chairman ofWoodbury, Jensen, Kesler & Swinton, a Salt Lake City law firm.

James Andress has joined the board at Genetics Institute Inc.(NASDAQ:GENI) of Cambridge, Mass. Andress had been chairmanof SmithKline Beecham plc and president and chief operatingofficer of Sterling Drug Inc.

William D. Phillips, Ph.D., has been elected a director atCelgene Corp. Phillips was associate director for industrialtechnology of the Office of Science and Technology Policy.Celgene (NASDAQ:CELG) of Warren, N.J., is developing fine andspecialty chemicals and proprietary hazardous wastebiotreatment systems.

(c) 1997 American Health Consultants. All rights reserved.